TY - JOUR
T1 - Case report
T2 - Non-Alzheimer's disease tauopathy with logopenic variant primary progressive aphasia diagnosed using amyloid and tau PET
AU - Momota, Yuki
AU - Konishi, Mika
AU - Takahata, Keisuke
AU - Kishimoto, Taishiro
AU - Tezuka, Toshiki
AU - Bun, Shogyoku
AU - Tabuchi, Hajime
AU - Ito, Daisuke
AU - Mimura, Masaru
N1 - Funding Information:
18F-florzolotau, the tau PET tracer used for this research, was provided by APRINOIA Therapeutics Inc. The authors would like to thank Dr. Jin Nakahara of the Department of Neurology, Dr. Masahiro Jinzaki of the Department of Diagnostic Radiology, and Mr. Kiyotaka Nakajima and the staff of the Division of Nuclear Medicine and Department of Radiology for their help with the PET examinations and image processing at Keio University School of Medicine; they would also like to thank Dr. Kenji Tagai, Dr. Hitoshi Shimada, and Dr. Makoto Higuchi of the Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Funding Information:
This work was supported by the Japan Agency for Medical Research and Development under Grant Number JP17pc0101006 to MM.
Publisher Copyright:
Copyright © 2022 Momota, Konishi, Takahata, Kishimoto, Tezuka, Bun, Tabuchi, Ito and Mimura.
PY - 2022/11/15
Y1 - 2022/11/15
N2 - We report a patient with logopenic variant primary progressive aphasia (lv-PPA) who was diagnosed as having non-Alzheimer's disease (AD) tauopathy after multiple biophysical/biological examinations, including amyloid and 18F-florzolotau tau positron emission tomography (PET), had been performed. A woman in her late 60s who had previously been diagnosed as having AD was referred to us for a further, detailed examination. She had been unaware of any symptoms at the time of AD diagnosis, but she subsequently became gradually aware of a speech impairment. She talked nearly completely and fluently, although she occasionally exhibited word-finding difficulty and made phonological errors during naming, word fluency testing, and sentence repetition; these findings met the criteria for the diagnosis of lv-PPA, which is known to be observed more commonly in AD than in other proteinopathies. Magnetic resonance imaging, single photon emission computed tomography, and plasma phosphorylated tau and plasma neurofilament light chain measurements showed an AD-like pattern. However, both 11C-Pittsburgh compound-B and 18F-florbetaben amyloid PET showed negative results, whereas 18F-florzolotau tau PET yielded positive results, with radio signals predominantly in the left superior temporal gyrus, middle temporal gyrus, supramarginal gyrus, and frontal operculum. Whole-genome sequencing revealed no known dominantly inherited mutations in AD or frontotemporal lobar degeneration genes, including the genes encoding amyloid precursor protein, microtubule-associated protein tau, presenilin 1 and 2. To the best of our knowledge, this patient was a rare case of lv-PPA who was diagnosed as having non-AD tauopathy based on the results of multiple examinations, including whole-genome sequencing, plasma measurement, and amyloid and 18F-florzolotau tau PET. This case underscores the clinicopathologically heterogeneous nature of this syndrome.
AB - We report a patient with logopenic variant primary progressive aphasia (lv-PPA) who was diagnosed as having non-Alzheimer's disease (AD) tauopathy after multiple biophysical/biological examinations, including amyloid and 18F-florzolotau tau positron emission tomography (PET), had been performed. A woman in her late 60s who had previously been diagnosed as having AD was referred to us for a further, detailed examination. She had been unaware of any symptoms at the time of AD diagnosis, but she subsequently became gradually aware of a speech impairment. She talked nearly completely and fluently, although she occasionally exhibited word-finding difficulty and made phonological errors during naming, word fluency testing, and sentence repetition; these findings met the criteria for the diagnosis of lv-PPA, which is known to be observed more commonly in AD than in other proteinopathies. Magnetic resonance imaging, single photon emission computed tomography, and plasma phosphorylated tau and plasma neurofilament light chain measurements showed an AD-like pattern. However, both 11C-Pittsburgh compound-B and 18F-florbetaben amyloid PET showed negative results, whereas 18F-florzolotau tau PET yielded positive results, with radio signals predominantly in the left superior temporal gyrus, middle temporal gyrus, supramarginal gyrus, and frontal operculum. Whole-genome sequencing revealed no known dominantly inherited mutations in AD or frontotemporal lobar degeneration genes, including the genes encoding amyloid precursor protein, microtubule-associated protein tau, presenilin 1 and 2. To the best of our knowledge, this patient was a rare case of lv-PPA who was diagnosed as having non-AD tauopathy based on the results of multiple examinations, including whole-genome sequencing, plasma measurement, and amyloid and 18F-florzolotau tau PET. This case underscores the clinicopathologically heterogeneous nature of this syndrome.
KW - Alzheimer's disease
KW - frontotemporal lobar degeneration
KW - logopenic variant
KW - positron emission tomography
KW - primary progressive aphasia
KW - tauopathy
UR - http://www.scopus.com/inward/record.url?scp=85143119778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143119778&partnerID=8YFLogxK
U2 - 10.3389/fneur.2022.1049113
DO - 10.3389/fneur.2022.1049113
M3 - Article
AN - SCOPUS:85143119778
SN - 1664-2295
VL - 13
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 1049113
ER -